PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals — Q4 2021 Earnings Presentation

31 slides from PhaseBio Pharmaceuticals's earnings presentation, Mar 24, 2022

  1. Slide 1: Corporate Overview March 24, 2022

    Corporate Overview March 24, 2022

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business str

  3. Slide 3: Company Overview: Therapeutic Focus and Milestones

    Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat cardiovascular diseases Product Candidates Bentracimab (PB2452) Novel agent in Phase 3 development for immediate and sustained reversal of ticagrelor, the preferred antipla

  4. Slide 4: A Clinical Stage, Cardiovascular Focused Biopharmaceutical Company

    Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Target2 Bentracimab Reversal of Ticagrelor Antiplatelet Activity Mid 2022 Planned BLA submission PB6440 Resistant Hypertension 2H 2022 Planned submission of Investigational New Drug application (IND) Partnering Opportu

  5. Slide 5: Corporate

    ) Corporate

  6. Slide 6: Experienced Management Team

    6 Experienced Management Team JONATHAN MOW Chief Executive Officer SUSAN ARNOLD, PhD SVP Technical Operations GLEN BURKHARDT SVP Human Resources KRIS HANSON General Counsel JOHN LEE, MD, PhD, FACC Chief Medical Officer JOHN SHARP Chief Financial Officer JONATHAN BIRCHALL Chief Commercial Officer Des

  7. Slide 7: Q4 2021 Financial Highlights

    • Sub-license revenue: $0.1M • Operating expense: $32.2M  R&D: $27.4M  SG&A: $4.9M • Loss from operations: ($32.1M) • Net Loss of ($43.1M) or ($0.90) per share, basic and diluted  48.1M shares used for computing Q4 2021 net loss per share • Cash and cash equivalents as of 12/31/2021: $41.8M • Ava

  8. Slide 8: Bentracimab (PB2452) Reversal Agent for Ticagrelor

    Bentracimab (PB2452) Reversal Agent for Ticagrelor

  9. Slide 9: Bentracimab: Urgent Surgery or Intervention

    Bentracimab 9 URGENT SURGERY OR INTERVENTION • Currently oral P2Y12 agents, including ticagrelor, require a 5-day washout prior to surgery1,2  Urgent surgery often cannot wait 5 days  Higher thrombotic risk during washout • In Phase 1 and Phase 2a studies, bentracimab observed to immediately and s

  10. Slide 10: Current Dilemma in Managing Surgical Patients

    • Early surgery = Bleed risk Current Dilemma in Managing Surgical Patients 10 5d - Ticagrelor washout Risk of bleeding Risk of thrombosis and procedural delay Bentracimab Bentracimab has to potential to eliminate this dilemma • Later surgery = Thrombosis risk

  11. Slide 11: Well-Characterized Mechanism of Reversal of Ticagrelor

    BentracimabBentracimab: Well-Characterized Mechanism of Reversal of Ticagrelor 11 1. 2. 3. 4. 5. 6. ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation Bentracimab binds to free ticagrelor with very high affinity This is a r

  12. Slide 12: Bentracimab Phase 2A Data

    Bentracimab Phase 2A Data 12 Adverse Events PBO (N=6) Bentracimab (N=17) Any AE – no. 13 20 Subjects with AE – no. (%) 5 (83%) 10 (59%) Dry mouth 1 0 Infrequent bowel movements 1 0 Nausea 1 1 Feeling hot (r) 0 2 Infusion site bruising 1 0 Infusion site erythema 1 0 Infusion site extravasation 0 1 Ve

  13. Slide 13: Pivotal Program for Bentracimab

    Bentracimab 13 Pivotal Program for Bentracimab 2019 2020 2021 2022 2023 Phase 2B: 50-80 year old volunteers CompletedPhase 2APhase 1 NEJM FDA Breakthrough Therapy FDA EOP1 EMA PRIME Designation N=200, 150 randomized to receive bentracimab N=150, major bleeding + urgent surgery patients Final N=200 P

  14. Slide 14: Phase 2B: Reversal of Ticagrelor and Safety

    Bentracimab 14 • Bentracimab achieved primary PRU endpoint of ticagrelor reversal Statistically significant reduction in % inhibition of PRU within 4 hours Speed of action and duration of response reversal similar to Phase 1 and 2A studies • Safety profile in the Phase 2B study consistent with Pha

  15. Slide 15: REVERSE-IT: Bentracimab Pivotal Phase Trial Overview

    bentracimab 15 REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview • REVERSE-IT: Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial • Open-label, single-arm study in patients with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure • To

  16. Slide 16: REVERSE-IT Interim Phase 3 Published in NEJM Evidence

    bentracimab Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery Deepak L. Bhatt, MD, MPH, Charles V. Pollack, Jr., MD, C. David Mazer, MD, Dominick J. Angiolillo, MD, PhD, Ph. Gabriel Steg, MD, Stefan K. James, MD, PhD, Jeffrey I. Weitz, MD, Rohit Ramnath, PhD, Susan E. Arnold,

  17. Slide 17: REVERSE-IT: Baseline Characteristics

    bentracimab REVERSE-IT: Baseline Characteristics 17https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047

  18. Slide 18: REVERSE-IT: Platelet Reversal

    bentracimab PRU analysis in surgical vs bleeding patients REVERSE-IT: Platelet Reversal 18 PRU analysis in all patients (N=150) (N=8) (N=142) https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047

  19. Slide 19: REVERSE-IT: Adjudicated Surgical Hemostasis

    bentracimab Adjudicated and Investigator-Reported Surgical Outcomes REVERSE-IT: Adjudicated Surgical Hemostasis 19https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047

  20. Slide 20: REVERSE-IT: Adjudicated Bleeding Hemostasis

    bentracimab Adjudicated and Investigator-Reported Bleeding Outcomes REVERSE-IT: Adjudicated Bleeding Hemostasis 20https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047

  21. Slide 21: REVERSE-IT: No Platelet Rebound Activity

    bentracimab P-selectin in surgical and bleeding patients Mean platelet volume in surgical and bleeding patients Effect of Bentracimab Treatment on P-Selectin and Mean Platelet Volume (MPV). Soluble P-selectin and MPV were measured pre-dose and at multiple timepoints post-initiation of bentracimab tr

  22. Slide 22: REVERSE-IT: Adjudicated Thrombotic Events

    bentracimab Adjudicated Thrombotic Events Occurring Post-Reversal REVERSE-IT: Adjudicated Thrombotic Events 22https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047

  23. Slide 23: REVERSE-IT: Bentracimab vs. Other Reversal Agents Thrombotic Events

    bentracimab Post-Reversal Thrombotic Events within 30 Days REVERSE-IT: Bentracimab vs. Other Reversal Agents Thrombotic Events 23 1. https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047 2. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran

  24. Slide 24: Expect Continued Long-Term Rx Growth of Ticagrelor

    Bentracimab Expect Continued Long-Term Rx Growth of Ticagrelor Bentracimab approval has the potential to drive continued positive momentum • Brilinta/Brilique sales in 2021 were approximately $1.5B  Pandemic impact dampened 2020 and 2021 growth • In February 2019, Brilinta Phase 3 THEMIS1 trial met

  25. Slide 25: Lipitor Analog Points to Potential Increase in Post-LOE Ticagrelor Share

    Lipitor Analog Points to Potential ~2.5X Increase in Post-LOE Ticagrelor Market Share Within the P2Y12 Inhibitor Class 25 51.1% 0% 10% 20% 30% 40% 50% 60% M ol ec ul e St an da rd U ni ts S ha re Atorvastatin/Lipitor Fluvastatin/Lescol Lovastatin/Altoprev Pitavastatin/Livalo Pravastatin/Pravachol Ro

  26. Slide 26: US Patients on P2Y12 Inhibitors

    BentracimabUS Patients on P2Y12 Inhibitors: Potential for Significant Long-Term Ticagrelor Patient 26 0.4 3.8 0.2 2.02.2 0.2 Clopidogrel Prasugrel Ticagrelor US Patients on P2Y12 Inhibitors (millions) 2019 2029 (est.) Continued AZ Promotion Bentracimab Launch Brilinta Patent Expiry Potential Drivers

  27. Slide 27: Bentracimab Addressable Market: Current and Future Estimates

    Bentracimab Bentracimab Patient Opportunity 27 1. 2019 P2Y12 class patient count analysis: Iqvia, MIDAS tablet volume 2. Bleeding events are defined as an inpatient admission with a diagnosis code for a bleed 3. Urgent surgery/procedure is defined as an emergency room visit where a surgery/procedure

  28. Slide 28: PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension

    PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension

  29. Slide 29: Resistant Hypertension: Large, growing patient population with high unmet need

    PB6440 Resistant Hypertension: Large, growing patient population, coupled with a high unmet need, creates an attractive opportunity for a novel therapy • Upwards of 10 million patients in the United States have resistant hypertension and are at risk for serious, costly medical consequences (stroke,

  30. Slide 30: PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2)

    PB6440 CYP11B Potency and Selectivity (IC50, μM) Human Monkey CYP11B2 CYP11B1# Selectivity CYP11B2 CYP11B1 Selectivity PB6440 0.024 4.859 202 0.016 5.802 363 LCI699* 0.0007 0.013 19 0.016 0.059 3.7 PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2) Selectivity and Potency Demonstrated in

  31. Slide 31: PB6440: A Promising CYP11B2 Inhibitor

    PB6440: A Promising CYP11B2 Inhibitor 31 Characteristics Of PB6440 Potential for multiple, high-value indications High in vitro selectivity for CYP11B2 over CYP11B1 High in vitro selectivity for CYP11B2 over drug metabolizing/other steroidal CYPs High oral bioavailability Long half-life in vivo cons

PhaseBio Pharmaceuticals — Q4 2021 Earnings Presentation on 6ix